H.B. Fuller's $943 million bid for Advanced Medical Solutions (AMS) is about to face its most important test yet. Two shareholder meetings have been scheduled for August 12, 2026 in London, and the outcome will determine whether the deal moves forward toward completion. Approval requires a majority representing at least 75% in value of shares voted, a threshold that reflects the structure typically used in UK takeover transactions and one that leaves relatively little room for a divided shareholder base.
Why Two Meetings, Not One
UK acquisitions structured as a scheme of arrangement, the mechanism commonly used for this type of takeover, generally require separate approvals covering different aspects of the transaction. One meeting typically addresses shareholder approval of the scheme itself, while a second, often a general meeting, handles related resolutions needed to implement it, such as amendments to the company's articles of association. Both need to pass for the deal to proceed, which is why AMS shareholders are being asked to attend two distinct meetings on the same day rather than a single combined vote.
This structure isn't unique to the H.B. Fuller-AMS deal, it's standard practice for UK public company takeovers, but it does mean the outcome depends on clearing two separate approval thresholds rather than one.
What the 75% Threshold Actually Requires
The 75% figure refers to value, not headcount, meaning approval depends on shareholders representing at least three-quarters of the total value of shares voted at the meeting, rather than simply a majority of individual shareholders. This is a meaningfully higher bar than a simple majority vote, and it's the standard threshold under UK takeover code requirements for scheme-of-arrangement transactions. A few points worth understanding about how this works in practice:
The threshold applies to shares actually voted, not to the total shares outstanding, meaning shareholder turnout at the meeting has a direct bearing on how achievable the threshold is.
Large institutional shareholders often carry outsized influence under a value-based threshold, since a small number of major holders can represent a significant share of the total value being voted.
This is separate from, though related to, the broader shareholder sentiment reflected in public opposition from investors like Ancora Holdings on the H.B. Fuller side of the transaction, since Ancora's opposition concerns H.B. Fuller's own shareholders, not AMS's.
What Happens If the Vote Passes
Assuming AMS shareholders clear both the scheme approval and the related resolutions on August 12, the transaction would move toward the next stage of completion, which typically involves court sanction of the scheme, since UK scheme-of-arrangement transactions require approval from the relevant court in addition to shareholder consent. Regulatory clearances, where applicable, would also need to be finalized before the deal can formally close. The shareholder vote is a necessary milestone, but not the final step in the process.
For buyers and suppliers watching the timeline, a successful August 12 vote would meaningfully de-risk the deal's completion and likely accelerate integration planning between the two companies.
What a Failed Vote Would Mean
A failure to clear the 75% threshold would be a significant setback, though not necessarily fatal to the transaction depending on how close the vote falls and whether revised terms could be negotiated. Scheme-of-arrangement deals that fail to secure shareholder approval typically require either a renegotiation of terms, a switch to an alternative offer structure, or in some cases, abandonment of the transaction entirely. Given the scale of strategic rationale H.B. Fuller has attached to this acquisition, a failed vote would likely trigger a swift public response from both companies regarding next steps.
What Buyers and Suppliers Should Watch This Week
The August 12 shareholder meetings represent the clearest near-term signal yet on whether this acquisition will proceed as planned. A passed vote would move the deal toward court sanction and eventual completion, while a failed vote would introduce meaningful uncertainty into a transaction that has already drawn public scrutiny from activist investors. Procurement teams and suppliers with exposure to either company should treat the days following August 12 as a key checkpoint for reassessing how quickly integration, and any related shifts in commercial terms or account structures, is likely to unfold.
Ready to source adhesive raw materials from verified global suppliers? Explore competitive offers on our platform today.
